Diabetes Health Professional
Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Reference Charts
Professional Issues Archives
Print | Email | Share | Comments (2)

Altea Partners With Amylin and Lilly to Develop 12-Hour Byetta Skin Patch

Apr 7, 2009

The patch, in a 12- and a 24-hour form, will use the company’s proprietary PassPort Transdermal Delivery System.

Buoyed by its recent successful phase 1 human clinical trial of a patch that delivers basal insulin through the skin, Atlanta-based Altea Therapeutics says it will work with Eli Lilly and Company and Amylin Pharmaceuticals, Inc., to develop a daily transdermal patch that deliver sustained levels of Byetta (exenatide). The patch, in a 12- and a 24-hour form, will use the company's proprietary PassPort Transdermal Delivery System. Lilly and Amylin will fund all development, manufacturing, and marketing activities for the product. 

In its basal insulin patch study, Altea tested a 12-hour patch that delivered a steady therapeutic level of insulin to wearers. The company reported that its patch, which substituted for insulin injections, successfully provided sufficient and sustained doses. Because insulin therapy currently requires injections and needles, many patients are resistant to its use. Doctors and healthcare providers are hoping that the convenience and pain-free delivery offered by the insulin patch will encourage people with diabetes to begin insulin therapy sooner. 

Similarly, Amylin and Lilly are hoping that Byetta, its injectable drug for controlling glucose and appetite, will achieve greater use and higher compliance rates if patients can take it in a non-injectable form. Although the drug is self-administered using pens with extremely short, thin needles that produce mild stings at worst, many people still shy away from the drug because of them.


Categories: Byetta, Diabetes, Diabetes, Insulin, Medications Research, Professional Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 2 comments - Apr 7, 2009

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.